EIDD-2801 shows efficacy against COVID-19 in human cells and mice
Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
List view / Grid view
Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
Ursolic acid was shown to halt the progression of chronic multiple sclerosis (MS) and reverse the damage already caused in a mouse model of the disease.
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
A study has revealed that a sponge endemic to an Indonesian bay produces manzamine A, a compound which inhibits proteins in cervical cancers.
A study has demonstrated that the anti-parasitic drug ivermectin may be effective against SARS-CoV-2, the virus which causes COVID-19.
Researchers have demonstrated that cysteinase, a new drug compound, can starve pancreatic cells of cysteine supply, causing ferroptosis.
Researchers have developed two small molecules which target two components of the circadian rhythm and could be used to lengthen the body clock.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
A new compound, called FL118, was effective at combatting multiple myeloma in advanced stages of the condition in patient samples as well as mice, say researchers.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
Exposing umbilical cord blood to NOV proteins causes an increase in functional haematopoietic stem cells (HSCs) and could provide a more effective transplant option for blood cancer patients.
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.